7 March 2022 - Sotorasib Is indicated as monotherapy for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small-cell lung cancer who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.
The SMC has today accepted Amgen’s first in class drug, Lumykras (sotorasib), for use on an interim basis by NHS Scotland as monotherapy for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small-cell lung cancer, who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.